Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENLIGHT-AML: A Phase 1, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT07084584 is registered in ClinicalTrials.gov with Galecto Biotech AB as lead sponsor.

NCT NCT07084584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07084584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENLIGHT-AML: A Phase 1, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Galecto Biotech AB
Phase
Phase 1
Overall status
Withdrawn
Start date
June 10, 2026
Completion date
October 10, 2029
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia (aml)